{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Diseases&page=18", "query": { "condition": "Pancreatic Diseases", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 3322, "total_pages": 333, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Diseases&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Diseases&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:35:22.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003548", "title": "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aminocamptothecin colloidal dispersion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003548" }, { "nct_id": "NCT03840278", "title": "The Bihormonal iLet Bionic Pancreas Feasibility Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Bihormonal iLet Bionic Pancreas", "type": "DEVICE" }, { "name": "Insulin-only Bionic Pancreas", "type": "DEVICE" }, { "name": "Dasiglucagon", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-05-15", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840278" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT02420691", "title": "Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Digestive System Neuroendocrine Neoplasm", "Duodenal Neuroendocrine Tumor G1", "Functional Pancreatic Neuroendocrine Tumor", "Gastric Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Nonfunctional Pancreatic Neuroendocrine Tumor", "Thymus Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-08-25", "completion_date": "2019-06-05", "has_results": true, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420691" }, { "nct_id": "NCT02797132", "title": "Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "LUM/IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 62, "start_date": "2016-05", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 17, "location_summary": "Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02797132" }, { "nct_id": "NCT03752398", "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Excluding Uveal Melanoma)", "Cervical Carcinoma", "Pancreatic Carcinoma", "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Cancer", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced Solid Tumors", "Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "XmAb®23104", "type": "BIOLOGICAL" }, { "name": "Yervoy® (ipilimumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2019-05-01", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 18, "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03752398" }, { "nct_id": "NCT04843306", "title": "Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreas Cancer" ], "interventions": [ { "name": "Biofeedback", "type": "BEHAVIORAL" }, { "name": "Active Breathing Control Technique", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-06-03", "completion_date": "2023-08-18", "has_results": false, "last_update_posted_date": "2024-06-07", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843306" }, { "nct_id": "NCT04690738", "title": "Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Exocrine Pancreatic Insufficiency", "Weight Gain" ], "interventions": [ { "name": "Fecal Elastase Concentration", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2020-08-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04690738" }, { "nct_id": "NCT02650635", "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Melanoma of the Skin", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Colorectal Cancer", "Stage IVA Pancreatic Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02-05", "completion_date": "2017-06-01", "has_results": false, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650635" }, { "nct_id": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "FT536", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Avelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Atezolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Trastuzumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Amivantamab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-05-31", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-15T11:35:22.384Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395052" } ] }